slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
216,211-216,240 of 319,975
14
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
15
The superscript 3 in '2000^3' appears to be a typo or formatting error in the source slide.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
16
The slide contrasts a large incumbent's metrics with the company's own USP.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · Competition1 hit
17
The slide outlines CE marking in Europe and the ongoing FDA PMA review process, including specific audit and inspection history.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
18
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
19
The slide uses a numbered list format to present future product roadmap items.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
20
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
21
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
22
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
01
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
02
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
03
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
04
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
05
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
06
The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
08
Includes a detailed biological mechanism diagram showing the interaction of KOR, dynorphin, and neurotransmitters.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Solution1 hit
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
15
Includes qualitative expert testimonials regarding pricing and market access.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Market Sizing1 hit
16
The diagram illustrates a decision-tree process based on clinical trial outcomes.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
17
Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
19
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
21
The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit